Safety of Monoclonal Antibodies in Myeloma

KEITH STEWART, MB, CHB

Wednesday, February 01, 2017

Keith Stewart, MB, ChB from Mayo Clinic in Scottsdale, discusses the use of monoclonal antibodies for treatment in multiple myeloma.

While infusion reactions can occur, pre-medication is recommended. Also, reactions do not usually persist past the first infusion. For daratumumab, these reactions can also affect the upper respiratory system. Also in daratumumab, the agent can affect red cell cross-matching for transfusion. Therefore, all cross-matching should take place before infusions.

To learn more about these treatments, watch Monoclonal Antibodies in Multiple Myeloma.

Discussions >>

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.